01.08.2023 13:02:13
|
IDEXX Laboratories Increases 2023 Earnings Outlook
(RTTNews) - IDEXX Laboratories, Inc. (IDXX) increased 2023 EPS outlook to $9.64 - $9.90, a year-over-year increase of 20% - 23% as reported and 24% - 27% on a comparable basis, including approximately 12% combined EPS growth benefit from a customer contract resolution payment in first quarter and lapping of discrete 2022 R&D investments.
The company updated its full year revenue growth outlook range to 8.5% - 10% as reported and organically. This reflects no changes to the outlook for organic revenue growth at the high end of the range and an increase of 1% at the low end, the company noted. This corresponds to a range of $3.66 billion - $3.715 billion.
Second quarter net income to stockholders increased to $224.2 million from $132.0 million, prior year. Earnings per share was $2.67, an increase of 71% as reported and 77% on a comparable basis. On average, nine analysts polled by Thomson Reuters expected the company to report profit per share of $2.47, for the quarter.
Second quarter revenues were $944 million, an increase of 10% reported and 10% organic, driven by Companion Animal Group growth of 11% reported and organic and Water revenue growth of 10% reported and 9% organic. Analysts on average had estimated $934.42 million in revenue.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu IDEXX Laboratoriesmehr Nachrichten
03.02.25 |
Schwacher Wochentag in New York: NASDAQ Composite beendet den Handel im Minus (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 verbucht zum Handelsende Verluste (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 zum Ende des Montagshandels schwächer (finanzen.at) | |
03.02.25 |
Verluste in New York: NASDAQ Composite nachmittags in Rot (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 am Montagnachmittag schwächer (finanzen.at) | |
03.02.25 |
Handel in New York: S&P 500 legt den Rückwärtsgang ein (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 präsentiert sich mittags schwächer (finanzen.at) | |
03.02.25 |
Zurückhaltung in New York: NASDAQ Composite mittags in Rot (finanzen.at) |
Analysen zu IDEXX Laboratoriesmehr Analysen
Aktien in diesem Artikel
IDEXX Laboratories | 444,20 | -2,74% |
|